High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B

Calvin Q. Pan; Myron Tong; Kris V. Kowdley; Ke Qin Hu; Ting Tsung Chang; Ching Lung Lai; Seung Kew Yoon; Samuel S. Lee; David Cohen; Hong Tang; Naoky Tsai

doi:10.1016/j.cgh.2012.03.016

High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B

Calvin Q. Pan
, Myron Tong
, Kris V. Kowdley
, Ke Qin Hu
, Ting Tsung Chang
, Ching Lung Lai
, Seung Kew Yoon
, Samuel S. Lee
, David Cohen
, Hong Tang
, Naoky Tsai

Division of Gastroenterology

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.

Original language	English
Pages (from-to)	1047-1050.e1
Journal	Clinical Gastroenterology and Hepatology
Volume	10
Issue number	9
DOIs	https://doi.org/10.1016/j.cgh.2012.03.016
State	Published - Sep 2012

Bibliographical note

Funding Information:
Conflicts of interest These authors disclose the following: Calvin Q. Pan has received research grants from Gilead , Bristol-Myers Squibb , Novartis , Idenix , Roche , and Schering Plough and has also served as a consultant, adviser, and on speakers bureau for Gilead, Bristol-Myers Squibb, Novartis, Idenix, Roche, Schering Plough, Onyx, Three Rivers, Salix, Genentech, Vertex, and Pharmasset. Ke-Qin Hu has participated in speakers bureaus and has received grants/research support from Bristol-Myers Squibb , Gilead , and Merck . Kris V. Kowdley has received research grants/support from Bristol-Myers Squibb , Intercept , Abbott , Pharmasset , Merck , Mochida , and Conatus ; has served as a consultant for Novartis; and has also received honoraria for participation in advisory boards for Vertex, Pharmasset, Merck, and Gilead. Ching-Lung Lai received honoraria from Bristol-Myers Squibb for participation in lectures. Samuel S. Lee has participated as a consultant for Bristol-Myers Squibb, Gilead, Janssen, Merck, Novartis, Pharmasset, Roche, and Vertex; has received research support from Bristol-Myers Squibb, Gilead, Merck, Roche, Novartis, Pharmasset, and Vertex; and has been a speaker for Bristol-Myers Squibb, Gilead, Merck, and Roche. David Cohen and Hong Tang are employees of Bristol-Myers Squibb. Naoky Tsai has participated in advisory boards and speakers bureaus for Bristol-Myers Squibb and Gilead and received research grants from Bristol-Myers Squibb and Gilead . The remaining authors disclose no conflicts.

Funding Information:
Funding The study was funded by Bristol-Myers Squibb.

Keywords

Antiviral Therapy
Hepatitis B Virus
Nucleos(t)ide Analogue

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cgh.2012.03.016

Cite this

Pan, C. Q., Tong, M., Kowdley, K. V., Hu, K. Q., Chang, T. T., Lai, C. L., Yoon, S. K., Lee, S. S., Cohen, D., Tang, H., & Tsai, N. (2012). High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 10(9), 1047-1050.e1. https://doi.org/10.1016/j.cgh.2012.03.016

@article{9eb3ec1ea1d845ceaa346da6843e7c95,

title = "High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B",

abstract = "There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95\% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76\% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40\% (26 of 65) achieved HBeAg loss, and 18\% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.",

keywords = "Antiviral Therapy, Hepatitis B Virus, Nucleos(t)ide Analogue",

author = "Pan, \{Calvin Q.\} and Myron Tong and Kowdley, \{Kris V.\} and Hu, \{Ke Qin\} and Chang, \{Ting Tsung\} and Lai, \{Ching Lung\} and Yoon, \{Seung Kew\} and Lee, \{Samuel S.\} and David Cohen and Hong Tang and Naoky Tsai",

note = "Funding Information: Conflicts of interest These authors disclose the following: Calvin Q. Pan has received research grants from Gilead , Bristol-Myers Squibb , Novartis , Idenix , Roche , and Schering Plough and has also served as a consultant, adviser, and on speakers bureau for Gilead, Bristol-Myers Squibb, Novartis, Idenix, Roche, Schering Plough, Onyx, Three Rivers, Salix, Genentech, Vertex, and Pharmasset. Ke-Qin Hu has participated in speakers bureaus and has received grants/research support from Bristol-Myers Squibb , Gilead , and Merck . Kris V. Kowdley has received research grants/support from Bristol-Myers Squibb , Intercept , Abbott , Pharmasset , Merck , Mochida , and Conatus ; has served as a consultant for Novartis; and has also received honoraria for participation in advisory boards for Vertex, Pharmasset, Merck, and Gilead. Ching-Lung Lai received honoraria from Bristol-Myers Squibb for participation in lectures. Samuel S. Lee has participated as a consultant for Bristol-Myers Squibb, Gilead, Janssen, Merck, Novartis, Pharmasset, Roche, and Vertex; has received research support from Bristol-Myers Squibb, Gilead, Merck, Roche, Novartis, Pharmasset, and Vertex; and has been a speaker for Bristol-Myers Squibb, Gilead, Merck, and Roche. David Cohen and Hong Tang are employees of Bristol-Myers Squibb. Naoky Tsai has participated in advisory boards and speakers bureaus for Bristol-Myers Squibb and Gilead and received research grants from Bristol-Myers Squibb and Gilead . The remaining authors disclose no conflicts. Funding Information: Funding The study was funded by Bristol-Myers Squibb. ",

year = "2012",

month = sep,

doi = "10.1016/j.cgh.2012.03.016",

language = "English",

volume = "10",

pages = "1047--1050.e1",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders",

number = "9",

}

Pan, CQ, Tong, M, Kowdley, KV, Hu, KQ, Chang, TT, Lai, CL, Yoon, SK, Lee, SS, Cohen, D, Tang, H & Tsai, N 2012, 'High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B', Clinical Gastroenterology and Hepatology, vol. 10, no. 9, pp. 1047-1050.e1. https://doi.org/10.1016/j.cgh.2012.03.016

TY - JOUR

T1 - High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B

AU - Pan, Calvin Q.

AU - Tong, Myron

AU - Kowdley, Kris V.

AU - Hu, Ke Qin

AU - Chang, Ting Tsung

AU - Lai, Ching Lung

AU - Yoon, Seung Kew

AU - Lee, Samuel S.

AU - Cohen, David

AU - Tang, Hong

AU - Tsai, Naoky

N1 - Funding Information: Conflicts of interest These authors disclose the following: Calvin Q. Pan has received research grants from Gilead , Bristol-Myers Squibb , Novartis , Idenix , Roche , and Schering Plough and has also served as a consultant, adviser, and on speakers bureau for Gilead, Bristol-Myers Squibb, Novartis, Idenix, Roche, Schering Plough, Onyx, Three Rivers, Salix, Genentech, Vertex, and Pharmasset. Ke-Qin Hu has participated in speakers bureaus and has received grants/research support from Bristol-Myers Squibb , Gilead , and Merck . Kris V. Kowdley has received research grants/support from Bristol-Myers Squibb , Intercept , Abbott , Pharmasset , Merck , Mochida , and Conatus ; has served as a consultant for Novartis; and has also received honoraria for participation in advisory boards for Vertex, Pharmasset, Merck, and Gilead. Ching-Lung Lai received honoraria from Bristol-Myers Squibb for participation in lectures. Samuel S. Lee has participated as a consultant for Bristol-Myers Squibb, Gilead, Janssen, Merck, Novartis, Pharmasset, Roche, and Vertex; has received research support from Bristol-Myers Squibb, Gilead, Merck, Roche, Novartis, Pharmasset, and Vertex; and has been a speaker for Bristol-Myers Squibb, Gilead, Merck, and Roche. David Cohen and Hong Tang are employees of Bristol-Myers Squibb. Naoky Tsai has participated in advisory boards and speakers bureaus for Bristol-Myers Squibb and Gilead and received research grants from Bristol-Myers Squibb and Gilead . The remaining authors disclose no conflicts. Funding Information: Funding The study was funded by Bristol-Myers Squibb.

PY - 2012/9

Y1 - 2012/9

N2 - There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.

AB - There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.

KW - Antiviral Therapy

KW - Hepatitis B Virus

KW - Nucleos(t)ide Analogue

UR - https://www.scopus.com/pages/publications/84865319280

U2 - 10.1016/j.cgh.2012.03.016

DO - 10.1016/j.cgh.2012.03.016

M3 - Article

C2 - 22475742

AN - SCOPUS:84865319280

SN - 1542-3565

VL - 10

SP - 1047-1050.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 9

ER -

High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this